

### AMENDMENTS TO THE SPECIFICATION

First paragraph in column 2:

“The term “anti-neoplastic” or “anti-tumor” refers herein to the (a) chemotherapeutic inhibition of arrest of the growth, and (b) to the destruction of mammalian benign (for example leiomyomas)[[.]] and/or malignant tissues (such as leukemias[[.]] or lymphomas), ~~and leiomyomas~~ found in various organs and tissues of the body.”

Column 4, beginning at line 38:

“Accordingly, it is a principal object of the present invention to provide compositions for the inhibition or arrest of the growth or for the destruction of mammalian benign (for example leiomyomas) and/or malignant tumors ~~lymphomas~~, (for example leiomyomas[[.]] and leukemias, etc.).”

Column 4, beginning at line 57:

“The present invention achieves the above objects, among others, and overcomes the limitations of the prior art by providing, an a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidence by their low toxicity, and molecular actions. Such drugs include as active ingredients one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating malignant neoplasms (such as leukemias[[.]] and lymphomas, and/or benign neoplasms (such as leiomyomas[[]]).”